DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

September 8, 2022

Increase Cancer and Fibrosis Treatment Options Through Next Generation Sequencing

Endeavor Biomedicines logo

The End Brain Cancer Initiative (EBCI), www.EndBrainCancer.org, is thrilled to announce expansion of their mission as it relates to increased patient disease education/awareness/outreach & access to advanced treatment options, diagnostics and clinical trials, including Next Generation Sequencing (NGS) as the organization partners with Endeavor BioMedicines, to advance these efforts on behalf of patients"

Endeavor logo

The Endeavor Biomedicines Story

With advances in next-generation sequencing and molecular profiling, we now have the tools to uncover the genetic culprits of disease. We can go after targets and indications we were not scientifically capable of investigating in the past. And we can finally bring patients best-in-class medicines across a spectrum of indications that target the core drivers of disease – making a significant impact even in terminal conditions.

At Endeavor BioMedicines, they are pursuing novel science and developing precision medicines. They combine advancements in technology with insights into the causes of disease to develop best-in-class medicines with the potential to treat the most severe health conditions, including cancer and fibrosis. 


Endeavor QR code

Scan the QR code or click on it to learn more about ENV-101 for PTCH-1 LOF cancer treatment.


ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram